معرفی
Richard Schottenfeld, MD, is a Senior Research Scientist at Yale School of Medicine's Department of Psychiatry and affiliated faculty at the Yale Institute for Global Health. His work focuses on improving opioid dependence treatment through integrated behavioral and pharmacological approaches, particularly for co-occurring disorders like chronic pain. He has pioneered studies on buprenorphine maintenance therapy and global health initiatives in Malaysia, Iran, and China.
Education:
- MD from Yale University (1976)
Research Interests:
- Efficacy of opioid agonist therapies (e.g., buprenorphine, methadone)
- Integration of addiction treatment into primary care
- Behavioral interventions for HIV risk reduction
- Global health strategies for substance use disorders
Notable Achievements:
- Founded Yale's Addiction Psychiatry Residency Training Program
- Recipient of the Nyswander-Dole Award (2004)
- Conducted landmark trials on buprenorphine and naltrexone in Malaysia
Publications: Dr. Schottenfeld has contributed to peer-reviewed research on MOUD accessibility, international treatment models, and barriers to care for marginalized populations. His recent work emphasizes improving engagement for Black patients in opioid treatment programs.
Labs/Teams: Collaborates with the Center for Interdisciplinary Research on AIDS, Connecticut Mental Health Center, and the Yale Global Mental Health Program.
